Literature DB >> 15480665

Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000.

Mar Ortega1, Montserrat Rovira, Manel Almela, Francesc Marco, Jorge Puig de la Bellacasa, José Antonio Martínez, Enric Carreras, Josep Mensa.   

Abstract

To examine shifts in the etiology, incidence, evolution, susceptibility, and patient mortality of bacterial and fungal bloodstream isolates (BSIs) from hematopoietic stem cell transplantation (HSCT) recipients, we reviewed the BSIs of 796 patients who underwent an HSCT in our institution during a 10-year period. Four hundred eighty-nine episodes of bacterial and fungal BSI were detected in 330 patients (41%). Three hundred ten isolates (63%) were gram-positive bacteria, 142 (29%) were gram-negative, and 18 and 19 isolates were different species of anaerobic organism and Candida spp. (both 4%). Coagulase-negative staphylococci (CoNS), with 210 isolates, were the organism most frequently isolated in each year of study and during the three phases of immune recovery after HSCT. The ratio of gram-positive to gram-negative has declined from 3.3 (1991-1992) to 1.8 (1999-2000). Crude mortality occurred in 47 cases of 489 BSI episodes (10%). Mortality according to groups was gram-negative, 7%; gram-positive, 9%; and anaerobic bacteria, 11%. Candida spp. was the group that accounted for the highest crude mortality, with 42%. Gram-positive microorganisms were isolated more often than gram-negative organisms, but the trend is reversing. CoNS were the leading pathogen during the 10 years of study and during the three phases of immune recovery after HSCT. Crude mortality of HSCT patients with BSI was low except for infections caused by Candida spp.

Entities:  

Mesh:

Year:  2004        PMID: 15480665     DOI: 10.1007/s00277-004-0909-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  14 in total

1.  Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study.

Authors:  Yoshitaka Inoue; Keiji Okinaka; Shigeo Fuji; Yoshihiro Inamoto; Naoyuki Uchida; Takashi Toya; Kazuhiro Ikegame; Tetsuya Eto; Yukiyasu Ozawa; Koji Iwato; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata; Takahiro Fukuda
Journal:  Bone Marrow Transplant       Date:  2021-04-19       Impact factor: 5.483

2.  Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline.

Authors:  Bridgette L Therriault; John W Wilson; Jason N Barreto; Lynn L Estes
Journal:  Mayo Clin Proc       Date:  2010-08       Impact factor: 7.616

3.  Bacteremia During Early Post-allogeneic Hematopoietic Stem Cell Transplantation Period: A Single Center Experience.

Authors:  Amro Mohamed Sedky El-Ghammaz
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-29       Impact factor: 0.900

4.  Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis.

Authors:  Worawut Choeyprasert; Suradej Hongeng; Usanarat Anurathapan; Samart Pakakasama
Journal:  Int J Hematol       Date:  2016-10-22       Impact factor: 2.490

5.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 6.  The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

Authors:  Christophe d'Enfert; Ann-Kristin Kaune; Leovigildo-Rey Alaban; Sayoni Chakraborty; Nathaniel Cole; Margot Delavy; Daria Kosmala; Benoît Marsaux; Ricardo Fróis-Martins; Moran Morelli; Diletta Rosati; Marisa Valentine; Zixuan Xie; Yoan Emritloll; Peter A Warn; Frédéric Bequet; Marie-Elisabeth Bougnoux; Stephanie Bornes; Mark S Gresnigt; Bernhard Hube; Ilse D Jacobsen; Mélanie Legrand; Salomé Leibundgut-Landmann; Chaysavanh Manichanh; Carol A Munro; Mihai G Netea; Karla Queiroz; Karine Roget; Vincent Thomas; Claudia Thoral; Pieter Van den Abbeele; Alan W Walker; Alistair J P Brown
Journal:  FEMS Microbiol Rev       Date:  2021-05-05       Impact factor: 16.408

Review 7.  Genetic susceptibility to Candida infections.

Authors:  Sanne P Smeekens; Frank L van de Veerdonk; Bart Jan Kullberg; Mihai G Netea
Journal:  EMBO Mol Med       Date:  2013-04-30       Impact factor: 12.137

8.  Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.

Authors:  Sung-Yeon Cho; Dong-Gun Lee; Su-Mi Choi; Chulmin Park; Hye-Sun Chun; Yeon-Joon Park; Jae-Ki Choi; Hyo-Jin Lee; Sun Hee Park; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  BMC Infect Dis       Date:  2015-02-18       Impact factor: 3.090

9.  Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children.

Authors:  Seung Beom Han; E Young Bae; Jae Wook Lee; Dong-Gun Lee; Nack-Gyun Chung; Dae-Chul Jeong; Bin Cho; Jin Han Kang; Hack-Ki Kim
Journal:  BMC Infect Dis       Date:  2013-06-17       Impact factor: 3.090

10.  Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study.

Authors:  Sung-Yeon Cho; Dong-Gun Lee; Su-Mi Choi; Jae-Cheol Kwon; Si-Hyun Kim; Jae-Ki Choi; Sun Hee Park; Yeon-Joon Park; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  BMC Infect Dis       Date:  2013-10-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.